EDIL3 and peripheral arterial disease: Clinical investigations into DEL-1’s therapeutic applications have shown promise, with the administration of DEL-1 plasmids leading to improved clinical manifestations in patients suffering from peripheral arterial disease, though the improvements did not achieve statistical significance, which warrants further study to conclusively determine efficacy (Grossman et al., 2007).